This is an NIH/NCI research grant for validating biomarker assays used in cancer detection, diagnosis, prognosis, monitoring, and treatment response, structured as a two-phase UH2/UH3 cooperative agreement. It fits labs, universities, hospitals, and small biotech companies that already have a working assay on human samples and need analytical or clinical validation. Retail, construction, transportation, and general service businesses have no realistic angle here and should not bother applying.
| Industry | Estimated fit |
|---|---|
| Healthcare & BiotechMatches your industry (clinical) | 68 |
| Environment & ConservationLimit: Closes in 26 days | 54 |
| Social Services & NonprofitLimit: Closes in 26 days | 54 |
| Arts & CultureLimit: Closes in 26 days | 53 |
| Energy & Clean TechLimit: Closes in 26 days | 53 |
| Education & TrainingLimit: Closes in 26 days | 52 |
| Industry | Estimated fit |
|---|---|
| Housing & Real EstateLimit: Closes in 26 days | 49 |
| Technology & SoftwareLimit: Closes in 26 days | 49 |
| Food & BeverageLimit: Closes in 26 days | 48 |
| Agriculture & FarmingLimit: Closes in 26 days | 47 |
| ManufacturingLimit: Closes in 26 days | 47 |
| Finance & BankingLimit: Closes in 26 days | 46 |
| Retail & E-CommerceLimit: Closes in 26 days | 44 |
| Transportation & LogisticsLimit: Closes in 26 days | 43 |
| Construction & InfrastructureLimit: Closes in 26 days | 42 |
These are our matcher’s estimates for a typical business in each industry. A real match depends on your size, your state and what you need the money for — check your own fit.
NIH/NCI cooperative agreement (UH2/UH3) funding validation of molecular, cellular, and imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response. Open to universities, hospitals, nonprofits, governments, tribes, and small or other for-profit businesses; clinical trials not allowed.
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientist.
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Topics
Open opportunities funding similar work, from the same funder or in the same place.
NIH BRAIN Initiative grants to develop tools and computational models for high-resolution, synchronous measurement of complex behaviors alongside neural activity in humans and other species. Eligible applicants include…
NIH/NCI K99/R00 career-development award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent tenure-track faculty positions; requires the candidate to lead an…
NIH/NCI UH3 cooperative agreement to clinically validate established molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, or treatment response using specimens from…
NIH/NCI K99/R00 award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent faculty careers. The applicant is typically the sponsoring institution; eligible…
NIH/NCI program funding revision applications to adapt and clinically validate molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response prediction.…
NIH/NCCIH forecasted R33 grant for multisite feasibility studies of mind and body interventions (meditation, yoga, acupuncture, music) on whole person health restoration. Eligible: small businesses, for-profits,…